In ALS, the intrathecal delivery of BDNF showed tolerance but inconclusive efficacy in clinical trials, while VEGF significantly delayed disease progression and preserved motor and neurological functions in murine models. The gene discussed is VEGFA; the disease is amyotrophic lateral sclerosis.